Glatix-M (Gliclazide 40 mg + Metformin HCI 500 mg Tablets): Uses, MOA, Benefits, and Recommended Dosage

  • Post category:Blog
  • Post comments:0 Comments
  • Reading time:7 mins read
Glatix-M: Gliclazide 40 mg + Metformin HCI 500 mg


Glatix-M, a pioneering formulation by Invision Medi Sciences, integrates the therapeutic potential of Gliclazide 40 mg and Metformin Hydrochloride 500 mg to offer a comprehensive solution for individuals managing type 2 diabetes. This article elucidates the synergistic mode of action (MOA) of Glatix-M in regulating blood glucose levels and enhancing insulin sensitivity.

Dual Action Mechanism:

Glatix-M operates through a multifaceted MOA, harnessing the distinct yet complementary actions of Gliclazide and Metformin Hydrochloride:

  • Gliclazide’s Insulin Secretagogue Action: Gliclazide stimulates insulin release from pancreatic beta cells, facilitating glucose uptake by peripheral tissues and ameliorating hyperglycemia.
  • Metformin’s Insulin Sensitizing Effect: Metformin improves insulin sensitivity in target tissues, suppresses hepatic gluconeogenesis, and enhances glucose uptake by skeletal muscles, fostering glycemic control.

Key Features of Glatix-M:

  1. Effective Glycemic Regulation:
    • Glatix-M offers robust glycemic control by synergistically modulating insulin secretion and sensitivity, curtailing the risk of hyperglycemia.
  2. Cardiometabolic Benefits:
    • Beyond glycemic management, Glatix-M may confer cardioprotective effects attributable to Metformin’s favorable impact on cardiovascular parameters.

Indications and Dosage:

  • Glatix-M is indicated for individuals with type 2 diabetes necessitating pharmacological intervention for glycemic control.
  • The dosing regimen of Glatix-M should be tailored to individual patient needs, typically commencing with one tablet once or twice daily with meals.

Recommended Dosage:

The recommended dosage of Glatix-M is tailored to suit each patient’s glycemic status and tolerance. Typically, healthcare providers initiate therapy with one tablet daily, adjusting the dose gradually to achieve optimal glycemic control.

Potential Side Effects:

While generally well-tolerated, Glatix-M may elicit adverse effects such as hypoglycemia, gastrointestinal disturbances, and allergic reactions. Vigilance and prompt reporting of adverse events to healthcare providers are imperative.


Glatix-M embodies Invision Medi Sciences’ commitment to delivering innovative diabetes management solutions. By amalgamating Gliclazide and Metformin Hydrochloride, Glatix-M offers a holistic therapeutic approach, empowering individuals to navigate their diabetes journey with confidence.

Related Combinations:

Explore our range of diabetes management solutions at Invision Medi Sciences.


How does Glatix-M help in managing type 2 diabetes?

Glatix-M combines Gliclazide and Metformin Hydrochloride to regulate blood sugar levels by stimulating insulin secretion and improving insulin sensitivity, respectively.

What is the recommended dosage regimen for Glatix-M?

The recommended dosage for Glatix-M varies and should be determined by a healthcare professional based on individual needs and response to treatment.

Can Glatix-M cause low blood sugar levels?

Glatix-M may lead to low blood sugar levels, especially if not taken as prescribed. It’s essential to monitor blood sugar levels regularly and report any concerns to a healthcare provider.

Are there any specific monitoring requirements while taking Glatix-M?

Regular monitoring of blood sugar levels and kidney function is typically recommended during treatment with Glatix-M. Patients should consult their healthcare provider for personalized guidance.

Who is eligible to take Glatix-M for diabetes management?

Glatix-M may be suitable for individuals diagnosed with type 2 diabetes who require additional medication to help control blood sugar levels. However, its use should be determined by a healthcare provider based on individual circumstances.

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.